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expression in a p38 MAP-kinase–dependent process
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Hyaluronan increases glomerular cyclooxygenase-2 protein molecular weight form maintains viscometric function
expression in a p38 MAP-kinase–dependent process. and provides extracellular matrix stabilization [1]. These
Background. Accumulation of the matrix glycosaminogly- features are most commonly recognized in the joint cap-can hyaluronan occurs in many types of renal injury but could
sule as the “shock absorbing” properties of synovial fluidfollow any provision of hyaluronan substrate to the kidney,
[2]. Hyaluronan is synthesized by hyaluronan synthetasefor example, through widespread use of supplementary glucos-
amine in osteoarthritic conditions. Hyaluronan can increase enzymes in many cell types [3] with specific receptors
cyclooxygenase-2 (COX-2) protein and prostaglandin produc- for its cellular binding [4]. Among the widely described
tion. This effect was characterized in rat renal glomeruli to consequences of hyaluronan binding and the subsequentdetermine the cellular mechanism of activation.
intracellular signals transduced are cell motility in woundMethods. Isolated glomeruli were treated with purified hya-
repair [5], tumor invasion [6] and developmental tissueluronan (molecular mass 2  105 D) for up to 24 hours.
Results. An increase in cyclooxygenase capacity and COX-2 morphogenesis [7]. In the context of normal renal func-
protein was shown to follow the activation of p38-mitogen- tion, medullary and papillary hyaluronan participates in
activated protein (MAP) kinase and to be inhibited by a specific the maintenance of oncotic pressure, but is not detected
pyridinyl imadazole inhibitor (SB 202190). Hyaluronan-induced
in the cortex [8]. However, increased hyaluronan levelsactivation of cytosolic phospholipase A2 also was shown to be
and presence in the cortex are found in renal insuffi-a p38 MAP kinase effect in these preparations. Prostaglandin
production was inhibited by COX-2–specific non-steroidal anti- ciency and end-stage renal failure [9, 10], and are charac-
inflammatory compounds (NS-398 and celecoxib) but, as shown teristic of inflammatory renal diseases [reviewed in 11].
for many non-steroidal anti-inflammatory drugs (NSAIDs), an Hyaluronan is present in experimentally-induced auto-
increase in COX-2 protein accompanied this inhibition.
immune crescentic glomerulonephritis in the rat [12] andConclusions. We propose that these findings have clinical
is raised in experimental renal ischemia [13] and rejectingrelevance. Prostaglandins have a number of important intrare-
nal regulatory effects leading to some debate over renal func- rat kidney grafts [14]. Raised serum hyaluronan indicates
tion with the use of NSAIDs. Where hyaluronan is increased, poor survival in human renal dialysis patients [15]. Many
p38 MAP-kinase–dependent provision of prostaglandin sub- of the reported effects of hyaluronan at a number of in-
strate, via activation of cytosolic phospholipase A2, and a con-
flammatory sites may be a consequence of inflammatorycomitant increase in cyclooxygenase-2 protein would raise re-
modification of hyaluronan to forms of lower molecularnal prostaglandin levels. While NSAID treatment can prevent
a rise in prostaglandin levels, it needs to be maintained to avoid mass [16] and the production of proinflammatory cyto-
possible exacerbation of pro-inflammatory conditions due to kines, chemokines and adhesion molecules that follows
increased COX-2 protein levels. interaction of this modified hyaluronan with CD44, the
foremost cell surface receptor for hyaluronan [17, 18].
Low and intermediate molecular weight hyaluronan forms
Hyaluronan is a non-sulfated glycosaminoglycan poly- can substantially increase the mRNA and protein levels
saccharide consisting of repeating disaccharide units of of cyclooxygenase-2 (COX-2), the inducible form of the
glucuronic acid and n-acetylglucosamine, which in a high enzyme regulating prostaglandin production, in cells of
non-renal [19] and renal origin [20]. COX-2 expression
appears necessary for renal development as mice lacking
Key words: mitogen-activated protein kinase, phospholipase A2, pros-
COX-2 due to targeted gene disruption develop a severetaglandin, glomerulus, renal injury, glycosaminoglycan polysaccharide,
wound repair. renal pathology and succumb to renal failure [21], and
inhibition of COX-2 in neonatal mice disrupts nephro-Received for publication April 18, 2001
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(NSAIDs) in adults. Some renoprotection attributed to Sweden). An oligomeric form of hyaluronan (Mr9.5 
104 D) was prepared from the high-molecular-weightCOX-2 inhibition [23] is tempered by potential renal
side effects of COX-2 inhibitor use, as prostaglandin form by sonication and filtration as described previously
[35]. Hyaluronan of molecular mass 2  105 D wasregulation of glomerular microcirculation and mainte-
nance of glomerular filtration rate (GFR) in conditions from ICN Biomedicals. SB202190 [4-(4-Fluophenyl)-2-
(4-hydroxyphenyl)-5-5(4-pyridyl)1H-imidazole] and NS-of volume depletion may be lost [24]. A paradoxical, but
consistent finding with the NSAID COX-2 inhibitors is 398 [N-(2-cyclohexylooxy-4-nitrophenylmethanesulpho-
namide] were obtained from Calbiochem-Novabiochemthat, while they are effective in inhibiting COX-2 activity,
there is often an accompanying up-regulation of COX-2 Pty. Ltd. (Alexandria, NSW, Australia). Celecoxib [4-[5-
(methylphenyl)-3(trifluoromethyl)-H-pyrazole-1-yl]ben-protein expression [25–27], leading to concern that, de-
pending on the biological duration of this COX-2 pro- zenesulphonamide] was prepared from Celebrex cap-
sules obtained from Searle, by ethanol extraction andtein, there may be a clinical overshoot of prostaglan-
din formation when an NSAID is discontinued but the chromatographically purified [36]. Polyclonal COX-2 an-
tiserum (Cayman Chemical #106116) was obtained fromprostaglandin substrate arachidonic acid remains avail-
able, most usually as a consequence of phospholipase A2 Sapphire Bioscience Pty. Ltd. (Crow’s Nest, NSW, Aus-
tralia). Prostaglandin E2 (PGE2) antibody was obtainedactivation. P38 mitogen-activated protein kinase (p38-
MAPK), which is most strongly activated by proinflam- from Assay Designs Inc. (Ann Arbor, MI, USA). Poly-
clonal phospho-specific p38-MAPK antibody (#9211S),matory cytokines and environmental stresses [27], pro-
vides phosphorylation-dependent activation of a specific p38MAPK antibody (#9212) were from New England
Biolabs Inc. (Beverley, MA, USA). Chemiluminescencecytosolic form of phospholipase A2 (cPLA2) [28, 29]. In
addition, there is now considerable evidence that p38- reagent (ECL) was from NEN Life Sciences Products
Inc. (Boston, MA, USA). [-32P] adenosine 5-triphos-MAPK regulates COX-2 at a transcriptional and post-
transcriptional level, resulting in increased COX-2 pro- phate ([-32P] ATP) was from Bresatec (Adelaide, South
Australia, Australia). MAPKAP kinase-2 Immunopre-tein [30, 31]. P38-MAPK activity and thus p38-MAPK-
dependent events are inhibited by cytokine-suppressing cipitation Kinase Assay Kit (p38-MAPK activity) was
obtained from Upstate Biotechnology (Lake Placid, NY,anti-inflammatory compounds (CSAIDs) [32]. Our pre-
vious work in experimental diabetes has shown that p38- USA). 1-Stearoyl-2-[1-14C] arachidonyl phosphatidylcho-
line and [5,6,8,11,12,14,15 (n)-3H] PGE2 were from Amer-MAPK is activated in glomeruli and glomerular mesan-
gial cells [33] and that these cells synthesize and secrete sham Pharmacia Biotech (Castle Hill, NSW, Australia).
hyaluronan in a prostaglandin-dependent manner [34].
Preparation and incubation of glomerular mesangialThis could provide support for an involvement of COX-2
cells and glomeruliin a positive feed-forward mechanism that would aug-
ment prostaglandin levels following hyaluronan synthe- Glomeruli were prepared from kidneys of Sprague-
Dawley rats (weighing 200 g) by differential sieving ofsis in the glomerulus, not only in diabetes, but apply broadly
in conditions of inflammation. The aim of the present inves- the kidney cortex [33, 34]. Approximately 10,000 to
15,000 glomeruli were isolated from each rat kidney.tigation was to establish whether hyaluronan-induced
increases in glomerular COX-2 protein and prostaglan- Pooled glomeruli from 8 to 10 kidneys were re-aliquoted
for immediate use or incubated in DMEM containingdin synthetic capacity are reliant on p38-MAPK activa-
tion, and the extent to which a p38-MAPK–dependent 0.5% fetal bovine serum (FBS; vol:vol) with the indicated
additions for up to 24 hours. When used, mesangial cellsroute to prostaglandin production can be modified by
CSAID and NSAID treatments. were grown from explanted glomerular cores, prepared
by digestion of intact glomeruli from control rats with
0.5 mg/mL collagenase Type V for 10 minutes at 37C.
METHODS
Explanted glomerular cores were maintained in DMEM
Reagents containing 20% FBS (vol:vol) and the resultant mesan-
gial cells used at passage 3. Mesangial cells were main-Collagenase Type V, -glycerophosphate, leupeptin,
phenylmethylsulfonyl fluoride (PMSF), protein G aga- tained in the above media containing 0.5% FBS (vol:vol)
up to 24 hours prior to use. When present, inhibitors ofrose and arachidonic acid were obtained from Sigma
Chemical Co. (St. Louis, MO, USA). Dulbecco’s modi- p38-MAPK (SB202190) or of COX-2 (NS-398, celecoxib)
were included over this time in the presence or absencefied Eagle’s medium (DMEM) was from Trace Biosci-
ences Pty. Ltd. (Castle Hill, New South Wales, Austra- of hyaluronan. Prior to acute use, cells and glomeruli
were washed rapidly with two changes of warmed me-lia). Fetal bovine serum (FBS) was from Commonwealth
Serum Laboratories (Parkville, Victoria, Australia). High dium and additions made for the indicated times before
cells were washed with ice-cold phosphate-buffered sa-molecular mass polymeric hyaluronan (Mr mean 5  106
D) was a gift from Dr. Ove Wik (Pharmacia, Uppsala, line (PBS) and lysed in the buffers described below.
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Western immunoblotting and immunoprecipitation
For immunoprecipitation and Western immunoblot-
ting, lysates were prepared from freshly isolated glomer-
uli or cultured mesangial cells in a buffer pH 7.5 containing
150 mmol/L NaCl, 5 mmol/L Tris, 2 mmol/L egtazic acid
Fig. 1. Effect of hyaluronan preparations on cyclooxygenase-2 (COX-2)
(EGTA), 1 mmol/L sodium vanadate, 40 mmol/L sodium protein expression in glomeruli. A representative Western immunoblot
of preparations of isolated glomeruli incubated under control conditionsfluoride, 50 mmol/L-glycerophosphate, 1% Triton X-100,
(lane 1) or with each of three hyaluronan preparations, hyaluronan0.25% deoxycholate, 0.15 U/mL aprotinin, 10 g/mL
polymer [HA(p), Mr mean 5  106 D, lane 2], a commercial hyaluronanleupeptin and 1 mmol/L PMSF. Proteins were resolved fragment [HA(f), Mr 2  105 D, lane 3) and a sonicated oligomeric
form [HA(s), Mr 9.5  104 D, lane 4) for 24 hours. Using the specificby sodium dodecyl sulfide-polyacrylamide gel electro-
COX-2 antibody described in the Methods section, the bands are de-phoresis (SDS-PAGE; 10% wt/vol acrylamide) and
tected that correspond to COX-2 protein.
transferred to polyvinylidene difluoride (PVDF) mem-
branes in Towbin Buffer (25 mmol/L Tris, pH 8.3, 192
mmol/L glycine, 20% methanol) in the absence of SDS,
Glomerular prostaglandin productionand COX-2 protein detected by probing with a poly-
We have previously determined that the E-series pros-clonal antibody and detection by ECL, or p38-MAPK
taglandins are major arachidonic acid metabolites inprotein detected by probing sequentially with phospho-
these glomerular preparations. Total immunoreactivespecific p38-MAPK antibody (#9211S) and p38-MAPK
PGE activity was measured in the incubation mediumantibody (#9212), detected by ECL. The p38-MAPK
of cells by specific RIA using an anti-PGE2 antibodysubstrate mitogen-activated protein kinase activating ki-
with 50% cross-reactivity for PGE1 with [5,6,8,11,12,nase-2 (MAPKAPK-2) was immunoprecipitated from
14,15 (n)-3H] PGE2 tracer (sp radioactivity 4.8-7.4 TBq/glomerular lysates by an anti-MAPKAPK-2 sheep poly-
mmol) as described previously [39].clonal IgG antibody coupled to protein G agarose. The
protein G agarose enzyme immunocomplex was washed
Cyclooxygenase activityand used for determination of MAPKAPK-2 activity.
A measure of maximal COX capacity, acute PGE pro-
MAPKAPK-2 activity duction was determined at the completion of incuba-
tion in the presence of hyaluronan and inhibitors for upMAPKAPK-2 is a serine/threonine kinase activated
to 24 hours, and, unless specified, followed the completeby phosphorylation by active p38-MAPK [32]. Activated
removal of incubation medium without re-addition ofMAPKAPK-2 was measured by phosphotransfer of [-32P]
ATP to a specific peptide substrate (KKLNRTLSVA) treatments or inhibitors. Glomeruli were incubated with
in the presence of MAPKAPK-2-protien G agarose en- a supramaximal concentration of arachidonic acid, 30
zyme immunocomplex in a commercially available assay. mol/L for 10 minutes at 37C and PGE production
measured. COX activity measured in this manner, de-
Cytosolic phospholipase A2 activity termines COX-1 [prostaglandin H synthase (PGH)-1,
Specific cPLA2 activity was measured in a glomerular PGHS-1], COX-2 (PGHS-2) and prostaglandin E (PGE)
cytosolic preparation by a previously published method synthase, which contribute to the formation of PGE [40].
[37, 38]. Briefly, glomeruli were washed with media, ho-
Statistical analysismogenized and a cytosolic fraction prepared by centrifu-
gation of the homogenates at 100,000  g for one hour Single comparison analysis of results was by the Stu-
at 4C. Aliquots of homogenate were pre-incubated with dent unpaired t test (two-tailed). Where multiple com-
10 mmol/L dithiothreitol (DTT), to remove possible in- parisons were made, significance was determined by
terference from secretory PLA2 activity and then incu- ANOVA in conjunction with Fisher’s least squares dif-
bated with 1-stearoyl-2-[1-14C] arachidonyl phosphatidyl ference. Significance was assumed at P  0.05.
choline substrate, 15 mol/L final concentration at 37C
for 30 minutes. The reaction was stopped by addition of RESULTS
2% (vol/vol) acetic acid in ethanol containing 100 g/mL
Hyaluronan-induced activation ofunlabeled arachidonic acid and substrate (arachidonyl
prostaglandin synthesisphosphatidyl choline) and product (arachidonic acid)
separated by thin layer chromatography, identified by Three preparations of hyaluronan, hyaluronan poly-
mer [HA(p), Mr mean 5 106 D], a commercial hyaluro-autoradiography and quantified after scintillation count-
ing of removed bands. cPLA2 activity in vitro was calcu- nan fragment [HA(f), Mr 2  105 D] and a sonicated
oligomeric form [HA(s), Mr 9.5  104 D] increasedlated as nmole of arachidonic acid hydrolyzed from sub-
strate in the presence of DTT and expressed as nmol/ COX-2 protein expression when incubated with isolated
glomeruli over 24 hours (Fig. 1). Treatment with eachmin/mg protein.
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form of p38-MAPK was seen up to three hours following
HA(f) exposure (data not shown). However, by four
hours an increase in p38-MAPK activation accompanied
the incubation of glomerular mesangial cells and glomer-
uli with HA(f). As shown in a representative Western
immunoblot blot (Fig. 4A), incubation with HA(f) (100
g/mL) increased phosphorylation of p38-MAPK in iso-
lated mesangial cells. Scanning densitometry quantita-
tion of this active p38-MAPK over four independent
experiments showed a significant increase (to 142 11%
of control incubations without HA(f), P  0.05). Activa-
tion of p38-MAPK was confirmed and quantified in glo-
merular preparations by the significant activation of the
p38-MAPK substrate, MAPKAPK-2 (Fig. 4B). Under
identical conditions there was a significant activation ofFig. 2. Time course of prostaglandin production in hyaluronan-treated
cPLA2 following the addition of HA(f) and further, thisglomeruli. Isolated glomeruli were incubated with hyaluronan [HA(f),
100g/mL] for up to 24 hours and prostaglandin release was determined increase in cPLA2 activity was no longer seen in prepara-
by radioimmunoassay as PGE1 and PGE2 (PGE). Values are expressed tions incubated with the p38-MAPK inhibitor and proto-as mean  SEM for four independent experiments. Statistically signifi-
typic CSAID, SB 202190 (Fig. 4C). The small but signifi-cant increase, *P  0.05, **P  0.001.
cant increase in PGE production seen in the time-course
studies was confirmed in this series of experiments and
it was shown further that the HA(f)-induced increase in
preparation was associated with a significant increase PGE production was prevented by SB 202190 (Fig. 4D).
in prostaglandin production when compared to control Confirmation of SB 202190 action was seen in the inhibi-
incubations over 24 hours (19220  4070, 12310  1695, tion of HA(f)-induced MAPKAPK-2 activation (from
6285  930 vs. 2190  270 pg PGE/mg protein/24 h; 4.32  0.14 to 0.93  0.10 pmol/min/mg protein, P 
mean  SEM; P  0.05, N 	 3). After 24-hour hyalu- 0.001). SB 202190 was without significant effect on basal
ronan treatments a significant increase in COX activity, activity of MAPKAPK-2, cPLA2 or PGE production.
determined as acute production of PGE from exogenous
P38-MAPK–dependent effects on COX-2 proteinarachidonic acid, was also seen (13180  220, 8100 
expression and COX activity465 and 5880 720 vs. 1860 210 pg PGE/mg protein/10
min; mean  SEM, P  0.05, N 	 3). As commercially Further investigations were made following 24 hours
available HA(f) has been extensively characterized and of exposure to HA(f). After this exposure there is a
shown to be free of protein and chondroitin sulfate [17, 41], significant increase in COX-2 protein expression, shown
this hyaluronan fragment preparation, HA(f), was used in a representative Western immunoblot (Fig. 5A). This
for further investigations. The time course of PGE for- immunoblot shows that COX-2 protein is evident, but
mation in isolated glomeruli after exposure to HA(f) is not prominent, in the basal state. Further, COX-2 protein
shown in Figure 2. A small but significant increase in expression is abolished by incubation with SB 202190 in
PGE formation was first seen at four hours. However in both basal and HA(f)-stimulated conditions. The corre-
all cases a major significant increase was seen with 24 sponding values for COX activity [determined as produc-
hour exposure, with an approximate 12-fold increase tion of PGE from exogenous arachidonic acid, indicative
over basal production. With PGE production confirmed of combined PGH-synthase (COX-1 and COX-2) and
in glomeruli, the 4- and 24-hour time points were investi- PGS-synthase activities], are shown for three indepen-
gated further to establish the events preceding an ob- dent experiments (Fig. 5B). Incubation with HA(f) over
served hyaluronan-induced increase of PGE synthesis. 24 hours caused a significant (10-fold) increase in COX
activity that was abolished by the concurrent presence
Activation of p38-MAPK and PGE formation of SB-202190. SB 202190 did not have a significant effect
Our preliminary investigations established that there on basal COX activity.
are substantial bands corresponding to the phosphory-
Effect of acute specific COX-2 inhibition onlated form of p38-MAPK under basal conditions in iso-
COX activity in glomerulilated glomeruli but no further phosphorylation, an indi-
cation of activation, was seen early in the course of HA(f) The effect of an acute addition of NS-398 or celecoxib
exposure. Figure 3 shows a representative Western im- on 24 hour HA(f)-induced COX activity was investigated
munoblot for p38-MAPK 15 and 30 minutes after HA(f) (Fig. 6). As shown previously (above) HA(f) significantly
increased COX-2 protein expression (Fig. 6A). This pro-exposure. Similarly, no increase in the phosphorylated
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Fig. 3. Effect of acute hyaluronan treatment on
p38-MAPK in isolated glomeruli. A representa-
tive Western immunoblot of preparations of iso-
lated glomeruli incubated under basal conditions
(indicated at 0 time, lanes 1 and 2) or with HA(f)
for 15 (lanes 3 and 4) or 30 minutes (lanes 5 and
6). Using specific phospho-p38 mitogen-activated
protein kinase (anti-phospho p38-MAPK, upper
panel) or p38-MAPK (anti-p38-MAPK, lower
panel) antibodies described in the Methods sec-
tion, bands are detected corresponding to the
phosphorylated forms of p38-MAPK protein and
total p38-MAPK.
tein expression was not altered by the acute addition of coxib. This measurement of PGE production is from
endogenously supplied substrate, as opposed to an excessNS-398 or celecoxib. However, the corresponding COX
activity (Fig. 6B) showed that acute addition of NS- arachidonic acid substrate provided in order to measure
398 or celecoxib over the incubation period when COX COX activity. Under endogenous conditions both SB-
capacity is determined, significantly reduced HA(f)- 202190, NS-398 and celecoxib significantly reduced HA(f)-
induced COX activity. Acute incubation with NS-398 induced PGE production.
or celecoxib is without significant effect on basal COX
activity.
DISCUSSION
Effect of NS-398 on COX activity These results indicate that hyaluronan in three physi-
cal forms can raise glomerular prostaglandin levels andThe time course of HA(f)-induced COX activity and
increase maximal cyclooxygenase capacity. Investigationsthe effect of NS-398 was investigated over 24 hours (Ta-
were made for the most part with a hyaluronan prepara-ble 1). There is a significant increase in HA(f)-induced
tion [HA(f), Mr 2  105 D) that has been characterizedCOX activity at 24 hours but no early time-dependent
previously by others, and shown to induce macrophageincrease in HA(f)-induced COX activity was seen. In
chemokine gene expression and maintenance of an in-contrast, over the first six hours of HA(f) exposure, con-
flammatory response [17] and to participate in gene ex-comitant NS-398 incubation increased HA(f)-induced
pression as a cofactor with inflammatory cytokines [41].COX activity, significantly at four and six hours after
This hyaluronan form may most closely represent hyalu-HA(f) exposure. Further, at early time points a signifi-
ronan exposed to the well-recognized process of post-cant increase in COX activity was seen in the presence
synthetic degradation [16]. An HA(f)-induced increaseof NS-398 alone. There was no alteration to this increase
in prostaglandin production is susceptible to both CSAIDin COX activity in the presence of SB202190 (10mol/L)
and NSAID inhibitors. Inhibition by a CSAID, using aincluded with NS-298 (10 mol/L) for one to six hours
prototypic compound (SB 202190) is suggested at, at(data not shown). Inhibition of COX activity was not
least, two points in the cascade of cellular events follow-seen when NS-398 was included together with HA(f) for
ing HA exposure: One, inhibition of cPLA2 which pro-24 hours (Table 1).
vides the substrate arachidonic acid for prostaglandin
Effect of celecoxib on COX activity production, the second an inhibition of the events leading
to a sustained level of COX-2 protein expression and COXIn a similar manner to NS-398, concomitant incubation
capacity. Both events follow inhibition of p38-MAPKwith celecoxib augmented HA(f)-induced and basal
activity. The inhibition of an induced COX activity, butCOX activity (Table 2). Moreover, inhibition of COX
not basal activity, by specific NSAID COX-2 inhibitorsactivity was not seen when celecoxib was included with
supports the involvement of the inducible isoform ofHA(f) for 24 hours. A simple explanation for the latter
cyclooxygenase (COX-2) in prostaglandin productionevent (seen with both NS-398 and celecoxib) may be that
an inhibitory effect is lost over 24 hours of incubation. following HA(f).
P38-MAPK is one member of a family of mitogen-However, a more complex situation of physiological rele-
vance may apply and is seen when endogenous prosta- activated protein kinases that are activated through a
canonical cascade of kinases activities. Once activated,glandin production is determined. Table 3 shows PGE
production measured over 24 hours in HA(f)-treated MAPKs can stimulate specific effector kinases [for exam-
ple, p38-MAPK activation of MAPK-activated proteinglomeruli in the presence of SB-202190, NS-398 or cele-
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Fig. 5. Effect of p38-MAPK inhibition on cyclooxygenase-2 (COX-2)
protein expression and COX activity in hyaluronan-treated glomeruli.
(A) A representative Western immunoblot of COX-2 protein from
glomeruli treated in the basal state (lanes 1 and 2) or with HA(f) for
24 hours in the absence (lanes 3 and 4) or presence of SB 202190
(lanes 5and 6) or SB 202190 alone (lanes 7 and 8). The corresponding
cyclooxygenase activities, determined as prostaglandin E (PGE) pro-
duction in response to 30 mol/L arachidonic acid over 10 minutes are
shown (B). Values are expressed as mean  SEM for four independent
experiments. Statistically significant difference, *P  0.005.
kinases (MAPKAPK) 2 and 3] [42, 43]. The MAPK
family can regulate multiple and diverse cytosolic and
nuclear events, including gene expression, and through
a specificity of the targeted response of members of the
MAPK family regulate the consequences of extracellular
stimuli including cell proliferation, cell survival or com-
mitment to cell death. In mammalian cells p38-MAPK
is thought to play an important role in the expression of
proinflammatory molecules and the regulation of cellular
responses during infection [44, 45]. The present study
is the first description of activation of p38-MAPK by
Fig. 4. Activation of p38-MAPK, cPLA2 and prostaglandin production hyaluronan (HA), to our knowledge. The mechanism is
in isolated mesangial cells and glomeruli. (A) Representative Western unknown but may be as straightforward as an activationimmunoblot of phosphorylated p38-MAPK protein in preparations of
of ras, one member of the small guanine nucleotide bind-isolated mesangial cells incubated in the basal state (lanes 1 and 2) or
with hyaluronan [HA(f), 100 g/mL, lanes 3 and 4] for four hours. (B) ing proteins superfamily, by hyaluronan [45] and the
Activation of MAPKAPK-2 following treatment of isolated glomeruli participation of ras in the cascade of cellular events pre-with HA(f), 100 g/mL for four hours. (C ) cPLA2 activity measured
ceding activation of p38-MAPK with other extracellularfollowing treatment of isolated glomeruli with HA(f), 100 g/mL for
four hours in the absence () or presence ( ) of SB 202190. (D) stimuli [46].
Prostaglandin production determined by radioimmunoassay following P38-MAPK is a well-described activator of cPLA2treatment of isolated glomeruli with HA(f) 100 g/mL for four hours
[28, 47] and evidence for this effect is now found in HA(f)-in the absence () or presence ( ) of SB 202190. Values are expressed
as mean  SEM for 4 independent experiments. Statistically significant stimulated glomeruli. P38-MAPK has been shown to be
difference, *P  0.005. required for the transcriptional activation of COX-2 in
response to lipopolysaccharide in human monocytes [48]
and to interleukin-1 (IL-1) [49]. In this latter study and
in many studies in mesangial cells including transforming
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Table 1. COX activity in glomerular preparations





hours Basal 100 lg/mL 10 lmol/L 10 lmol/L
1 55701805 61001945 114501625 108401440
2 54201590 80002010 113901645a 111701640a
4 69951745 83051600 148801970a,b 176701075a
6 107001845 110001720 168501230a,b 162551405
24 91551370 419352140a 459652420a 120851090
Values are expressed as mean  SEM for 4 independent experiments.
a Statistically significant difference from timed incubation under basal condi-
tions, P  0.05
b Statistically significant difference from timed incubation with HA(f) alone,
P  0.05
Table 2. COX activity in glomerular preparations





hours Basal 100 lg/mL 10 lmol/L 10 lmol/L
1 39001420 46501345 63901540 57401400
2 40151060 45951780 81351040a 85401005a
4 45951050 52051060 97101235a,b 9630975a
24 83701215 290651790a 324052010a 123501055
Values are expressed as mean  SEM for 3 independent experiments.
a Statistically significant difference from timed incubation under basal condi-
tions, P  0.05
b Statistically significant difference from timed incubation with HA(f) alone,
P  0.05
Table 3. HA(f)-induced prostaglandin E (PGE) production in
glomerular preparations
% Basal PGE production
HA(f)
Treatment Nil 100 lg/mL
Fig. 6. Effect of acute inhibition of COX-2 on hyaluronan-induced Inhibitor
COX-2 activity in isolated glomeruli. (A) A representative Western Nil 10019 1182207a
immunoblot of COX-2 protein from glomeruli in the basal state (lanes 1 SB 202190 10 lmol/L 9014 8112b
and 2) or treated with HA(f) for 24 hours (lanes 3 and 4). (B) Cyclooxy- NS-398 10 lmol/L 7714 7312b
genase activities, determined as PGE production in response to 30 Celecoxib 10 lmol/L 12332 28840a,b
mol/L arachidonic acid over 10 minutes in response to COX-2 inhibi-
Values are expressed % basal production (10805 2740 pg PGE produced/mgtion in isolated glomeruli pre-treated with HA(f). The COX-2 inhibitors
protein/24 h) and are shown as meanSEM for 4 independent experiments.NS-398 or celecoxib were absent () or present [( ) NS38 10 mol/L; a Statistically significant from incubation without HA(f), P  0.005() celebrex 10 mol/L] over this 10-minute incubation period. Values b Statistically significant from incubation with HA(f), P  0.005
are expressed as mean SEM for four independent experiments. Statis-
tically significant difference, *P  0.005.
there is increased phosphorylation of p38-MAPK and that
this is reflected in increased MAPKAPK-2 activation.growth factor-1 (TGF-1) stimulation [50], p38-MAPK
activation occurs rapidly following stimulation but also P38-MAPK has been widely investigated for an effect
on COX-2 at a translational and transcriptional level.it shows that this activation can be sustained. The lack
of rapid activation in response to HA(f) in isolated glo- IL-1–induced transcription of COX-2 in a human mi-
crovascular endothelial cell line has been shown to re-meruli in the present study indicates that hyaluronan is
not rapidly accessible to glomerular cells or that the cell- quire a combinatorial action of transcription factors, spe-
cifically activated protein-2 (AP2), nuclear factor-IL-6ular response is chronic rather than acute. It is clear,
however, that by four hours following HA(f) stimulation (NF-IL-6) and cAMP-responsive elements (CRE) [51].
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The involvement of an interleukin-responsive (NF-IL-6) widely. COX-2 has been shown to be regulated in glo-
and a cyclic AMP response element (CRE) may be of merular cells. Goppelt-Struebe, Stroebel and Hoppe
particular relevance to HA(f)-induced COX-2 tran- studied platelet-stimulated renal mesangial cells and
scriptional activation, as there is a demonstrated poten- found that the stability of COX-2 mRNA and COX-2
tial for increased renal cAMP production by PGE2 [52], protein differs markedly [59], and additionally that
which might be expected to follow HA(f)-induced PGE COX-2 mRNA is induced rapidly by platelet-related
production. In addition, hyaluronan can modify cellular stimuli such as lysophosphatidic acid [60] or platelet-
IL-1 release at some sites [53], but this has not been derived growth factor [59]. Others have shown that an
investigated in the kidney. However, the most commonly IL-1–induced increase in COX-2 mRNA occurs over
described effect of p38-MAPK on COX-2 activity is a much longer time course in mesangial cells [61]. While
regulation of gene expression by a post-transcriptional mRNA is rapidly degraded, COX-2 protein is stable for
mechanism involving cytoplasmic targets. COX-2 mRNA several hours, allowing protein levels to accumulate. We
is among many mRNAs that are rapidly degraded. One show that if hyaluronan levels are increased, then a stabi-
common feature in the genes from which these mRNAs lization of COX-2 mRNA can be expected with an atten-
are transcribed is a large 3-untranslated region (UTR) dant increase in COX-2 protein, an effect which is aug-
that contains numbers of highly conserved AUUUA mo-
mented by NSAIDs. However, inhibition of COX activitytifs or AU-rich-repeats [54–56]. Very recently, Lasa et al
requires the presence of the NSAID. Thus, the effecthave shown that a link between the widely-described ef-
on the multiple prostaglandin-related events in kidneyfect of p38-MAPK to stabilize COX-2 mRNA may be
function (on glomerular microcirculation, renal medul-found in p38-MAPK’s ability to alter the destabilizing
lary microcirculation, renin release, urinary concentra-interaction of a conserved AU-rich element with AU-
tion and dilution, and renal sodium and potassium excre-rich element/poly(U)binding factor [31]. The mechanism
tion [reviewed 52] may need to be considered when anhas not been described but does involve p38-MAPK
NSAID is discontinued. Increased hyaluronan levels mayactivation of MAPKAPK-2 [31]. The findings of the
previously have been thought to follow only clinically-present study closely resemble the sequence of events
recognized conditions [9, 10, 15, 62], but there is now anfollowing IL-1 in airway smooth muscle cells where
emergent situation in which elevated HA levels at renal,p38-MAPK activation initiates a sequence of phosphory-
and other sites requires further consideration. The widely-lation of cPLA2, COX-2 overexpression and rapid syn-
thesis of PGE2, and is abolished by p38-MAPK inhibition sold dietary supplement glucosamine sulfate has been
[29]. The present study shows that, overall, HA(f)-induced shown to have clinical efficacy in slowing the progression
changes would be most effectively abrogated by a CSAID of osteoarthritis [63]. An enhanced synovial production
p38-MAPK inhibitor. of hyaluronan has been proposed to explain the rapid
Shown also is the previously described finding that clinical response to high-dose glucosamine as it supplies
NSAIDs, including NS-398, can up-regulate COX-2 pro- one of the rate-limiting substrates for hyaluronan synthe-
tein expression after short- to medium-term exposure sis [64]. Our previous work has shown glucosamine to
[25–27, 57]. The most likely explanation for this effect be efficiently incorporated into glomerular hyaluronan
may be in the capacity of NS-398 and other NSAIDs in vitro [65]. A clinical scenario could be easily proposed
to bind to activate a peroxisome proliferator response that merges concomitant NSAID and glucosamine ther-
element in the promoter region of the COX-2 gene [54]. apy, using compounds that are extensively prescribed or
We show that the effect of NS-398 alone, as distinct self-administered, respectively. Under these conditions,
from HA(f), is not p38-MAPK-dependent, and thus it
until more is known, including the extent and molecularis unlikely to follow a COX-2 mRNA stabilization via
nature of renal hyaluronan formed following ingestionthis mechanism. We show also that the presence of an
of glucosamine and the maintenance of COX-2 proteinNSAID can block any increase in endogenous PGE pro-
in the presence of hyaluronan or other stimuli whichduction arising from an increase in COX-2 activity, but
raise cPLA2, including inflammation [29, 66], the renalthat cells pre-exposed to NSAID will increase PGE pro-
effect of NSAIDs should not be predicted. More gener-duction in the presence of raised levels of substrate ara-
ally, it is also suggested from these studies that, due tochidonic acid. As NS-398 and celecoxib binding to
a sustained COX-2 protein expression, acute exacerba-COX-2 protein is reversible [58], and this latter effect
tion of inflammatory prostaglandin production may oc-could be presumed to follow the rapid competition of
cur when NSAID therapy is intermittent or discontinued.arachidonic acid with any remaining inhibitor. Although
no in vivo role has been defined currently for an NSAID-
Reprint requests to Marjorie E. Dunlop, Ph.D., University of Mel-induced increase in COX-2 protein expression, we now
bourne, Department of Medicine, Royal Melbourne Hospital, Grattan
propose a clinically-relevant circumstance under which Street, Parkville, Victoria 3050, Australia.
E-mail: medunlop@unimelb.edu.auit should be considered in renal tissue and perhaps more
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